Actively Recruiting
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2023-10-23
107
Participants Needed
25
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
CONDITIONS
Official Title
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Volunteered to join the study and signed informed consent form with good compliance
- Age between 18 and 75 years old at time of consent
- Eastern Cooperative Oncology Group Performance Status score of 0-1
- Expected survival period longer than 3 months
- Diagnosed with CLL or SLL according to 2018 iwCLL guidelines
- Patients with SLL must have measurable lesions on CT or MRI
- Female participants of childbearing age agree to use contraceptive measures during the study and for 6 months after
- Negative pregnancy test within 7 days before enrollment
You will not qualify if you...
- Diagnosed with other malignant tumors within 3 years before first medication, except certain treated cancers with long disease-free survival
- Lymphoma or leukemia involving the central nervous system
- Previously received allogeneic hematopoietic stem cell transplantation
- Received autologous hematopoietic stem cell transplantation within 3 months before first medication
- Unresolved toxic reaction grade 1 or higher from previous treatments
- Arterial or venous thrombotic events within 6 months before first medication
- Any serious or uncontrollable diseases
- Received chemotherapy or radiotherapy within 4 weeks before first medication
- Received immune checkpoint inhibitors or CAR-T cell therapy within 12 weeks before first medication
- Received other small molecule anti-tumor treatments within 5 half-lives before first medication
- Previously treated with BCL-2 inhibitors
- Received vaccines within 4 weeks before first medication or planned vaccination during study
- Participated in other antineoplastic drug trials within 4 weeks before first medication
- Allergic to allopurinol or benzbromarone
- Investigator judgment excludes due to safety or study completion concerns
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 25 locations
1
Anqing Municipal Hospital
Anqing, Anhui, China, 246004
Actively Recruiting
2
Gansu province Wuwei tumour hospital
Wuwei, Gansu, China, 733000
Actively Recruiting
3
Sun Yat-Sen University Cancer Canter
Guangzhou, Guangdong, China, 510060
Actively Recruiting
4
Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China, 067400
Actively Recruiting
5
Harbin first hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
6
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150000
Actively Recruiting
7
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
8
Hunan Cancer Hospital
Changsha, Hunan, China, 410029
Actively Recruiting
9
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China, 210029
Actively Recruiting
10
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215004
Actively Recruiting
11
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
12
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
Actively Recruiting
13
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
14
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China, 110000
Actively Recruiting
15
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250063
Actively Recruiting
16
Linyi people's hospital
Linyi, Shandong, China, 276002
Actively Recruiting
17
Tai 'an Central Hospital
Tai’an, Shandong, China, 271000
Actively Recruiting
18
Shanghai Tongren Hospital
Shanghai, Shanghai Municipality, China, 200050
Actively Recruiting
19
Peace Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China, 460000
Actively Recruiting
20
Affiliated hospital of southwest medical university
Luzhou, Sichuan, China, 646000
Actively Recruiting
21
Mianyang Central Hospital
Mianyang, Sichuan, China, 621000
Actively Recruiting
22
Yibin Second People's Hospital
Yibin, Sichuan, China, 644000
Actively Recruiting
23
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
24
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang Uygur Autonomous Region, China, 830054
Actively Recruiting
25
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China, 315010
Actively Recruiting
Research Team
J
Jianyong Li, Doctor
CONTACT
K
Keshu Zhou, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here